BlueCross BlueShield Federal Employee Program

ADBRY
(tralokinumab-ldrm)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Adbry (tralokinumab-ldrm) is a human monoclonal IgG4 antibody that specifically binds to interleukin-13 (IL-13) and blocks its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2). This blocks the IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, and IgE (1).

Regulatory Status

FDA-approved indication: Adbry is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry can be used with or without topical corticosteroids (1).

Adbry has warnings for hypersensitivity reactions, conjunctivitis, keratitis, and parasitic (helminth) infections. Patients should be monitored and Adbry treatment should be discontinued if appropriate (1).

Prior to initiation of Adbry, patients should complete all age-appropriate vaccinations as recommended by current immunization guidelines. Live vaccines should be avoided while using Adbry (1).

The safety and effectiveness of Adbry in pediatric patients less than 12 years of age have not been established (1).

Summary

Adbry (tralokinumab-ldrm) is an interleukin-13 receptor antagonist indicated for the treatment of atopic dermatitis (eczema). Adbry has warnings for hypersensitivity reactions, conjunctivitis, keratitis, and parasitic (helminth) infections. Patients should be monitored and Adbry treatment should be discontinued if appropriate. The safety and effectiveness of Adbry in patients less than 12 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of

BlueCross BlueShield Federal Employee Program

ADBRY
(tralokinumab-ldrm)

Adbry while maintaining optimal therapeutic outcomes.

References

1. Adbry [package insert]. Madison, NJ: LEO Pharma Inc.; June 2024.